OtherOTC:EVFM

Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO

Retrieved on: 
Thursday, April 18, 2024
FDA, Patient, Lactic acid, Orange, Pregnancy, Woman, OTCQB, Hormone, Orange Book, Citric acid, Birth, Patent, SAN, Birth control

SAN DIEGO, April 18, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that the United States Patent and Trademark Office (USPTO) issued to the Company a Notice of Allowance for patent application 17/823,020 entitled, "Compositions and Methods for Enhancing the Efficacy of Contraceptive Microbicides." This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.

Key Points: 
  • This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.
  • The allowed claims cover methods of contraception with a composition that encompasses Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel.
  • The patent, when issued, will be Evofem's fifth patent for Phexxi in the United States.
  • "This patent allowance attests to the innovation Phexxi brings to contraception and a woman's ability to protect herself from unintended pregnancy with no hormones."

Evofem Biosciences Announces Financial Results for the Second Quarter of 2023

Retrieved on: 
Monday, August 14, 2023
DTC, Common stock, Note, 8-K, Lactic acid, Marketing, OTCQB, Research, COVID, Sale, Forecasting, SAN, Delaware General Corporation Law, Citric acid, FDA, Pharmaceutical industry, Security (finance), Series

SAN DIEGO, Aug. 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced financial results for the second quarter and first half of 2023.

Key Points: 
  • SAN DIEGO, Aug. 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced financial results for the second quarter and first half of 2023.
  • "This marks the second consecutive quarter in which our net product sales surpassed our sales and marketing costs.
  • "The reported net sales were lower than anticipated due to unexpected returns received in the second quarter of product with short-dated shelf life.
  • For the three months ended June 30, 2023, net product sales were $2.5 million compared to $6.0 million in the prior year period.

Evofem to Participate in the Virtual Investor Summer Spotlight Series

Retrieved on: 
Thursday, July 6, 2023
OTCQB, Senior, Q&A, SAN

SAN DIEGO, July 6, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) (the "Company") today announced that Saundra Pelletier, Chief Executive Officer, and Amy Raskopf, Senior Vice President, Investor Relations of Evofem, will participate in the Virtual Investor Summer Spotlight on Wednesday, July 12, 2023 at 4:00 p.m. ET. The virtual event will include a brief overview of the Company's business, a moderated roundtable discussion and an interactive Q&A session.

Key Points: 
  • -- Live moderated video webcast with members of Evofem management team on Wednesday, July 12th at 4:00 p.m.
  • ET --
    SAN DIEGO, July 6, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) (the "Company") today announced that Saundra Pelletier, Chief Executive Officer, and Amy Raskopf, Senior Vice President, Investor Relations of Evofem, will participate in the Virtual Investor Summer Spotlight on Wednesday, July 12, 2023 at 4:00 p.m.
  • The virtual event will include a brief overview of the Company's business, a moderated roundtable discussion and an interactive Q&A session.
  • A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

Evofem Appoints Ivy Zhang as Chief Financial Officer and Secretary

Retrieved on: 
Friday, April 14, 2023
University, Lactic acid, Controller, OTCQB, History, Accounting, Economics, EBITDA, SAN, Hedera, Ernst, CPA, CFO, Citric acid, Ernst & Young, Management, Virginia Tech

SAN DIEGO, April 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), today announced the appointment of Ivy Zhang as Chief Financial Officer (CFO) and Secretary, effective April 13, 2023.

Key Points: 
  • SAN DIEGO, April 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), today announced the appointment of Ivy Zhang as Chief Financial Officer (CFO) and Secretary, effective April 13, 2023.
  • Reporting to Chief Executive Officer Saundra Pelletier, Ms. Zhang will lead Evofem's finance organization and financial activities including financial planning and analysis, accounting, external audit, tax, controllership, and treasury functions.
  • "We are delighted to welcome Ivy back to Evofem as our chief financial officer and secretary.
  • Ms. Zhang is a seasoned finance executive with more than 14 years of financial and accounting experience spanning diverse industries, including pharmaceuticals and medical devices.

Costco Adds Phexxi® to Member Prescription Program

Retrieved on: 
Tuesday, January 10, 2023
Citric acid, The Fruit & Veggie Prescription Program, Pharmacy, Lactic acid, OTCQB, Woman, SAN, Health insurance, Costco, Lactic acid/citric acid/potassium bitartrate

"This program enables Costco members with no insurance or whose plans have denied coverage to fill their Phexxi prescriptions at a reduced cost."

Key Points: 
  • "This program enables Costco members with no insurance or whose plans have denied coverage to fill their Phexxi prescriptions at a reduced cost."
  • The Costco Member Prescription Program is a prescription drug discount card program that provides eligible Costco members and their eligible dependents the ability to obtain lower prices on Phexxi and other participating drugs at participating pharmacies.
  • Costco members who are uninsured and want to pay cash for their Phexxi prescription, or who have been denied coverage by their insurer, may use this program to fill their Phexxi prescriptions for less than the typical cash pay cost.
  • The pricing available through the discount card applies at their local Costco pharmacies, Costco mail order and thousands of participating neighborhood pharmacies.

Evofem Announces Issuance of U.S. Patent Covering Phexxi® Composition of Matter

Retrieved on: 
Friday, September 23, 2022
Securities Exchange Act of 1934, Health, Infection, Sex, Chlamydia, COVID-19, Woman, Human, FDA, Urinary tract infection, HIV, Gonorrhea, Company, Private Securities Litigation Reform Act, Pregnancy, History, Bacterial vaginosis, USPTO, Method, Orange Book, Reproductive health, Male, CDC, QIDP, Candidiasis, Patent, Annual report, Lactic acid, SAN, Citric acid, SEC, Orange, Birth control, Pharmaceutical industry, Animal, Lactic acid/citric acid/potassium bitartrate

SAN DIEGO, Sept. 23, 2022 /PRNewswire/ -- Evofem Biosciences (OTCPK: EVFM) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,439,610, which covers the composition of matter of Phexxi® (lactic acid, citric acid, potassium bitartrate).  

Key Points: 
  • 11,439,610, which covers the composition of matter of Phexxi (lactic acid, citric acid, potassium bitartrate).
  • "We are extremely pleased with the continued development of the Phexxi patent portfolio, which comprises more than 40 patents.
  • Top-line data from EVOGUARD, Evofem's registrational Phase 3 clinical trial evaluating Phexxi for these two potential new indications, are expected in mid-October.
  • Evofem now has the sole right in the United States to make, have made, market, and sell for any commercial purpose the composition of matter that comprises Phexxi.